Luke Miels takes the helm at GSK, tasked with turning a shrinking patent portfolio into a revenue engine. The new chief faces a 2025‑2026 window where key drug patents expire, threatening sales. Miels must rally the pipeline to meet a 15‑20% growth target in the next fiscal year and ahead.

GSK’s strategy hinges on repurposing existing molecules and accelerating late‑stage candidates. Analysts note that a successful pivot could offset a projected £3.5 billion decline in branded sales. Investors will watch quarterly earnings for signs of pipeline breakthroughs and any new licensing deals to support future growth and shareholder value in 2025.

Regulators will scrutinize any rapid approvals, while competitors eye GSK’s pipeline for partnership opportunities. Miels’ track record at Novartis and Bristol‑Myers Squibb suggests he can navigate complex approvals. Market watchers anticipate a strategic shift toward biologics and precision medicine in the coming quarters to drive revenue growth and shareholder returns.